RepliCel Life Sciences Inc.
REPCFOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$7000
P/E Ratio—
52W High$0.042835
52W Low$0.00001
RepliCel Life Sciences Inc. (REPCF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · REPCF · as of 2026-06-15
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.35M | $0.35M | $0.35M | $0.35M | $0.35M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.00M | $0.35M | $0.35M | $0.35M | $0.35M |
| Gross Margin %(computed) | 0.00% | 100.00% | 99.58% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.11M | $0.53M | $0.62M | $1.15M |
| G&A Expenses | $0.00M | $0.60M | $1.21M | $1.13M | $1.51M |
| Total Operating Expenses | $0.12M | $0.71M | $1.74M | $1.75M | $2.65M |
| Operating Income | $0.24M | ($0.36M) | ($1.39M) | ($1.39M) | ($2.30M) |
| Operating Margin %(computed) | 67.29% | -101.77% | -391.82% | -393.80% | -649.64% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.04M | $0.11M | $0.15M | $0.01M | $0.01M |
| Income Before Tax | ($0.25M) | ($0.10M) | ($0.31M) | ($0.74M) | ($4.07M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($0.40M) | ($0.10M) | ($0.31M) | ($0.74M) | ($4.07M) |
| Net Margin %(computed) | -113.63% | -27.50% | -88.20% | -210.04% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.01 | $-0.00 | $-0.01 | $-0.02 | $-0.13 |
| Wtd Avg Shares | 70.01M | 62.29M | 59.24M | 37.77M | 32.49M |
| EBITDA | $0.24M | ($0.36M) | ($1.39M) | ($0.74M) | ($4.07M) |
| EBITDA Margin %(computed) | 67.29% | -101.62% | -391.54% | -208.07% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · CAD · M
Explore more RepliCel Life Sciences Inc. data
About RepliCel Life Sciences Inc. (REPCF) Income Statement
RepliCel Life Sciences Inc. (REPCF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, REPCF reported revenue of $0.00B, gross profit of $0.00B (gross margin 0.00%), and net income of ($0.00B) — a net profit margin of -113.63%.
Frequently asked questions
REPCF · 4 questionsRepliCel Life Sciences Inc. (REPCF) reported revenue of $0.00B for 2025, down 0.1% year-over-year.
REPCF revenueREPCF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15